Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Trigger-point injections for post-mastectomy pain syndrome: a randomized double-blind controlled trial.

Created on 18 Nov 2026

Authors

Victor Figueiredo Leite, Rodrigo Guimarães de Andrade, Wilian Carlos Siena, Rafael Pereira de Freitas, Giovana de Andrade Resende, Christina May Moran de Brito

Published in

Einstein (Sao Paulo, Brazil). Volume 24. Pages eAO2250. Epub Nov 16, 2026.

Abstract

To evaluate the efficacy of trigger-point injections in individuals with post-mastectomy pain syndrome when combined with interdisciplinary rehabilitation and pharmacological treatment. Study design: Double-blind, sham-controlled clinical trial.
Participants with post-mastectomy pain syndrome were randomized to receive three weekly trigger-points, injections (active versus sham), combined with rehabilitation and pharmacological treatment. Primary outcomes included pain intensity measured by the numerical rating scale (NRS, 0-10), the number of active trigger points, and pressure pain thresholds across six predefined bilateral muscles. Assessments were performed at baseline and at 1 and 3 months post-intervention. Secondary outcomes included measures of neuropathic pain, central sensitization, disability, and shoulder range of motion.
Seventy one patients were enrolled, with a median pain duration of 13 months. At baseline, mean NRS was 7.0±1.5, neuropathic pain was present in 74.7%, central sensitization in 78.9%, and patients had an average of 3.8±1.7 active trigger points. No between-group differences were observed in NRS at any time point. At 1 month, pressure pain threshold in the ipsilateral upper trapezius muscle favored the Control Group (active=0.12±0.89 versus control=0.71±1.02; p=0.048). Conversely, the number of active trigger-points. was lower in the Active Group (active=1.95±2.28 versus control=3.00±2.11; p=0.048). No significant differences were found in secondary outcomes.
The addition of three weekly trigger-point injections to a rehabilitation and pharmacological treatment program for PMPS did not yield clinically meaningful improvements in pain or functional outcomes at 1 or 3 months.
NCT04267315.

PMID:
43049032
Bibliographic data and abstract were imported from PubMed on 18 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 7
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement